Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

228 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Carfilzomib, lenalidomide and dexamethasone followed by a second ASCT is an effective strategy in first relapse multiple myeloma: a study on behalf of the Chronic malignancies working party of the EBMT.
Tilmont R, Yakoub-Agha I, Eikema DJ, Zinger N, Haenel M, Schaap N, Arroyo CH, Schuermans C, Besemer B, Engelhardt M, Kuball J, Michieli M, Schub N, Wilson KMO, Bourhis JH, Mateos MV, Rabin N, Jost E, Kröger N, Moraleda JM, Za T, Hayden PJ, Beksac M, Mclornan D, Schönland S, Manier S. Tilmont R, et al. Among authors: schonland s. Bone Marrow Transplant. 2023 Nov;58(11):1182-1188. doi: 10.1038/s41409-023-02048-7. Epub 2023 Aug 5. Bone Marrow Transplant. 2023. PMID: 37543712 Free PMC article.
Extramedullary relapses after allogeneic non-myeloablative stem cell transplantation in multiple myeloma patients do not negatively affect treatment outcome.
Minnema MC, van de Donk NW, Zweegman S, Hegenbart U, Schonland S, Raymakers R, Zijlmans JM, Kersten MJ, Bos GM, Lokhorst HM. Minnema MC, et al. Among authors: schonland s. Bone Marrow Transplant. 2008 May;41(9):779-84. doi: 10.1038/sj.bmt.1705982. Epub 2008 Jan 14. Bone Marrow Transplant. 2008. PMID: 18195681
Postallograft lenalidomide induces strong NK cell-mediated antimyeloma activity and risk for T cell-mediated GvHD: Results from a phase I/II dose-finding study.
Wolschke C, Stübig T, Hegenbart U, Schönland S, Heinzelmann M, Hildebrandt Y, Ayuk F, Atanackovic D, Dreger P, Zander A, Kröger N. Wolschke C, et al. Among authors: schonland s. Exp Hematol. 2013 Feb;41(2):134-142.e3. doi: 10.1016/j.exphem.2012.10.004. Epub 2012 Oct 17. Exp Hematol. 2013. PMID: 23085463 Free article. Clinical Trial.
Reduced intensity-conditioned allogeneic stem cell transplantation for multiple myeloma relapsing or progressing after autologous transplantation: a study by the European Group for Blood and Marrow Transplantation.
Auner HW, Szydlo R, van Biezen A, Iacobelli S, Gahrton G, Milpied N, Volin L, Janssen J, Nguyen Quoc S, Michallet M, Schoemans H, El Cheikh J, Petersen E, Guilhot F, Schönland S, Ahlberg L, Morris C, Garderet L, de Witte T, Kröger N; Plasma Cell Dyscrasia Sub-committee of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Auner HW, et al. Among authors: schonland s. Bone Marrow Transplant. 2013 Nov;48(11):1395-400. doi: 10.1038/bmt.2013.73. Epub 2013 May 27. Bone Marrow Transplant. 2013. PMID: 23708704
Trends in autologous hematopoietic cell transplantation for multiple myeloma in Europe: increased use and improved outcomes in elderly patients in recent years.
Auner HW, Szydlo R, Hoek J, Goldschmidt H, Stoppa AM, Morgan GJ, Moreau P, Attal M, Marit G, Russell N, Brune M, Cook G, Sonneveld P, Schönland S, Garderet L, Kröger N. Auner HW, et al. Among authors: schonland s. Bone Marrow Transplant. 2015 Feb;50(2):209-15. doi: 10.1038/bmt.2014.255. Epub 2014 Nov 10. Bone Marrow Transplant. 2015. PMID: 25387088 Clinical Trial.
Impact of CR before and after allogeneic and autologous transplantation in multiple myeloma: results from the EBMT NMAM2000 prospective trial.
Iacobelli S, de Wreede LC, Schönland S, Björkstrand B, Hegenbart U, Gruber A, Greinix H, Volin L, Narni F, Carella AM, Beksac M, Bosi A, Milone G, Corradini P, Friberg K, van Biezen A, Goldschmidt H, de Witte T, Morris C, Niederwieser D, Garderet L, Kröger N, Gahrton G; EBMT CMWP, Plasma Cell Disorders Subcommittee. Iacobelli S, et al. Among authors: schonland s. Bone Marrow Transplant. 2015 Apr;50(4):505-10. doi: 10.1038/bmt.2014.310. Epub 2015 Jan 26. Bone Marrow Transplant. 2015. PMID: 25621805 Clinical Trial.
Comparison of upfront tandem autologous-allogeneic transplantation versus reduced intensity allogeneic transplantation for multiple myeloma.
Sahebi F, Iacobelli S, Biezen AV, Volin L, Dreger P, Michallet M, Ljungman PT, de Witte T, Henseler A, Schaap NP, López-Corral L, Poire X, Passweg J, Hamljadi RM, Thomas SH, Schonland S, Gahrton G, Morris C, KrÖger N, Garderet L. Sahebi F, et al. Among authors: schonland s. Bone Marrow Transplant. 2015 Jun;50(6):802-7. doi: 10.1038/bmt.2015.45. Epub 2015 Mar 23. Bone Marrow Transplant. 2015. PMID: 25798673
Allogeneic hematopoietic stem cell transplantation for poor-risk CLL: dissecting immune-modulating strategies for disease eradication and treatment of relapse.
Hahn M, Böttcher S, Dietrich S, Hegenbart U, Rieger M, Stadtherr P, Bondong A, Schulz R, Ritgen M, Schmitt T, Tran TH, Görner M, Herth I, Luft T, Schönland S, Witzens-Harig M, Zenz T, Kneba M, Ho AD, Dreger P. Hahn M, et al. Among authors: schonland s. Bone Marrow Transplant. 2015 Oct;50(10):1279-85. doi: 10.1038/bmt.2015.150. Epub 2015 Jul 6. Bone Marrow Transplant. 2015. PMID: 26146810
Second allogeneic transplantation for relapse of malignant disease: retrospective analysis of outcome and predictive factors by the EBMT.
Ruutu T, de Wreede LC, van Biezen A, Brand R, Mohty M, Dreger P, Duarte R, Peters C, Garderet L, Schönland S, Gratwohl A, Niederwieser D, de Witte T, Kröger N; European Society for Blood and Marrow Transplantation (EBMT). Ruutu T, et al. Among authors: schonland s. Bone Marrow Transplant. 2015 Dec;50(12):1542-50. doi: 10.1038/bmt.2015.186. Epub 2015 Sep 14. Bone Marrow Transplant. 2015. PMID: 26367221
Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working Party.
Sobh M, Michallet M, Gahrton G, Iacobelli S, van Biezen A, Schönland S, Petersen E, Schaap N, Bonifazi F, Volin L, Meijer E, Niederwieser D, El Cheikh J, Tabrizi R, Fegeux N, Finke J, Bunjes D, Cornelissen J, Einsele H, Bruno B, Potter M, Fanin R, Mohty M, Garderet L, Kröger N. Sobh M, et al. Among authors: schonland s. Leukemia. 2016 Oct;30(10):2047-2054. doi: 10.1038/leu.2016.101. Epub 2016 Apr 27. Leukemia. 2016. PMID: 27118410 Free article.
228 results